MYC and lymphoma: IHC analysis also helps define the double expressor DLBCL (c-MYC/BCL-2 overexpression, 25% of de-novo DLBCL cases) [22,23], while FISH determines the double/triple hit lymphomas (genetic rearrangement of c-MYC/BCL-2 or BCL-6, 6-14% of de-novo DLBCL cases) [19,20].